

G1
~~59 (Amended).~~ The recombinant polypeptide of claim 40 or 54, wherein said polypeptide contains one or more amino acid substitutions or deletions which do not substantially affect functional aspects of said CT polypeptide.

G2
61 (Amended). The recombinant polypeptide of claim 40 or 54, said polypeptide comprising at least 87 kDa.

62 (Amended). The recombinant polypeptide of claim 40 or 54, said polypeptide comprising at least 100 kDa.

G3
~~63 (Amended).~~ The recombinant polypeptide of claim 63, 64, or 65, wherein said polypeptide is immunologically identifiable with the protein encoded by the amino acid of SEQ ID NO:3.

~~70 (Amended).~~ The recombinant polypeptide of claim 63, 64, or 65, wherein said polypeptide contains one or more amino acid substitutions or deletions which do not substantially affect the functional aspects of said polypeptide.

G4
72 (Amended). The recombinant polypeptide of claim 63, 64, or 65, said polypeptide comprising at least 87 kDa.

73 (Amended). The recombinant polypeptide of claim 63, 64, or 65, said polypeptide comprising at least 100 kDa.

G5
~~79 (Amended).~~ The recombinant polypeptide of claim 74 or 75, wherein said polypeptide is immunologically identifiable with the protein encoded by the amino acid sequence of SEQ ID NO:3.

~~80 (Amended).~~ The recombinant polypeptide of claim 74 or 75, wherein said polypeptide contains one or more amino acid substitutions or deletions which do not

G5
Gould

~~sub~~ substantially affect functional aspects of said CT polypeptide and wherein said polypeptide ~~can~~ induce the production of antibodies to *Helicobacter pylori*.

G4

82 (Amended). The recombinant polypeptide of claim 74 or 75, said polypeptide comprising at least 87 kDa.

83 (Amended). The recombinant polypeptide of claim 74 or 75, said polypeptide comprising at least 100 kDa.

sub
H4

~~84 (Amended). An immunogenic, recombinant polypeptide comprising at least 5 amino acids expressed from at least 15 contiguous nucleotides of SEQ ID NO:2, wherein said polypeptide exhibits substantially no toxicity or substantially reduced toxicity and wherein said polypeptide can induce the production of antibodies to *Helicobacter pylori*.~~

G7

~~90 (Amended). The recombinant polypeptide of claim 84, 85, or 86, said polypeptide further comprising a *Helicobacter pylori* CT polypeptide, an immunogenic fragment thereof or an immunogenic derivative thereof, which is immunologically identifiable with the protein expressed by the polynucleotide sequence of SEQ ID NO:2.~~

91 (Amended). The recombinant polypeptide of claim 84, 85, or 86, wherein said polypeptide contains one or more amino acid substitutions or deletions which do not substantially affect the functional aspects of said antigen.

G4

93 (Amended). The recombinant polypeptide of claim 84, 85, or 86, said polypeptide comprising at least 87 kDa.

94 (Amended). The recombinant polypeptide of claim 84, 85, or 86, said polypeptide comprising at least 100 kDa.

G8
sub
H4

~~99 (Amended). A recombinant polypeptide of a *Helicobacter pylori* cytotoxin, wherein:~~

- G9
amend*
- (i) said cytotoxin causes the formation of vacuoles in eukaryotic cells,
 - (ii) said recombinant polypeptide exhibits substantially no toxicity, or substantially reduced toxicity,
 - (iii) said recombinant polypeptide can induce the production of antibodies to a *Helicobacter pylori* cytotoxin, and
 - (iv) said polypeptide is expressed from at least 15 contiguous nucleotides from SEQ ID NO:2.

100 (Amended). The recombinant polypeptide of claim 99, wherein said polypeptide is expressed from at least 30 contiguous nucleotides from SEQ ID NO:2.

101 (Amended). The recombinant polypeptide of claim 99, wherein said polypeptide is expressed from at least 45 contiguous nucleotides from SEQ ID NO:2.
